Biodyne Co

Biodyne Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biodyne Co (314930.KQ) as of Nov 13, 2026 is 652.26 M KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -864.01 M KRW — a change of -175.49% (higher).

EBITDA

652.26 MKRW

YoY

-175.49%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biodyne Co is 2025 652.26 M KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biodyne Co was 2024 -864.01 M KRW. It decreases by -175.49% higher compared to the previous year.

The Biodyne Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
451.16 M KRW
Jan 1, 2019
-1.49 B KRW
Jan 1, 2020
-1.64 B KRW
Jan 1, 2021
-2.13 B KRW
Jan 1, 2022
7.06 B KRW
Jan 1, 2023
-1.56 B KRW
Jan 1, 2024
-864.01 M KRW
Jan 1, 2025
652.26 M KRW
The Biodyne Co EBITDA history
YEAREBITDAYoY
652.26 MKRW-175.49%
-864.01 MKRW-44.54%
-1.56 BKRW-122.06%
7.06 BKRW-432.27%
-2.13 BKRW+29.90%
-1.64 BKRW+9.94%
-1.49 BKRW-429.91%
451.16 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biodyne Co Stock analysis

What does Biodyne Co do? Biodyne Co., Ltd. develops and sells cancer diagnosis solutions, including LBC diagnostic equipment and diagnostic reagent kits. The company's equipment lineup features PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO, targeting healthcare providers in domestic and international markets. Products are sold in Japan, Russia, Portugal, and Thailand, with domestic sales complementing overseas distribution. Revenue is generated through direct sales of diagnostic equipment and reagent kits to medical facilities and laboratories. Biodyne's primary customers are healthcare institutions requiring cancer screening and diagnostic tools, including hospitals and clinical laboratories. The firm's domestic market presence supports its international expansion into regions like Japan and Russia, where demand for advanced diagnostic solutions is growing. Sales of PATHPLORER series equipment and reagent kits form the core revenue streams, with no additional services or licensing models mentioned. The company focuses on a niche segment of cancer diagnostics, leveraging its equipment and reagent kits to serve both local and global healthcare systems. By offering standardized diagnostic solutions, Biodyne caters to the needs of medical professionals seeking reliable and efficient cancer detection methods. International markets such as Portugal and Thailand represent key growth areas alongside established domestic operations. Biodyne Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biodyne Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biodyne Co is 652.26 M KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biodyne Co changed from -864.01 M KRW to 652.26 M KRW, representing a -175.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Biodyne Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Biodyne Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biodyne Co

All Key Metrics — Biodyne Co